Although the clinical use of etomoxir has ceased because of adverse effects[90], the CPT1 inhibitor perhexiline can sensitize breast cancer cells to paclitaxel[91], and other CPT1 inhibitors[92] are currently being investigated for use in cancer therapy. Here, CPT1A is linked to breast cancer.